Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 134.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 134.
Diabetic Male and Female Volunteers Needed for Exercise Research Study 06-0062
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
PI: Regensteiner, Judith
  • 303-724-2255
  • katie.rogers@ucdenver.edu
Trouble Controlling your Type 2 Diabetes? 12-1529
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
PI: Wyatt, Holly
  • GI Dynamics
  • Jeanneanne.breen@ucdenver.edu
Project Safe - THE IMPACT OF MEDICAL MARIJUANA IN METROPOLITAN DENVER 11-0718
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
PI: Booth, Robert
  • 1-800-429-9240
  • Eric.Kovalsky@ucdenver.edu
Persons with active, moderate to severe ulcerative colitis needed 12-1408
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
PI: Gerich, Mark
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
3D Gait Analysis Participants Needed 13-1857
Research study investigating the coordination of walking
Subject with Spastic Cerebral Palsy Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Retrospective gait data must contain a complete lower body marker set and valid kinetic data. ● Only gait data trials of the subject walking unassisted will be used. ● Diagnosis of spastic cerebral palsy. ● Exhibits either stiff knee gait pattern, characterized by insufficient and delayed peak knee flexion during swing (less than 45), or crouch gait pattern, characterized by excessive hip flexion and knee flexion (greater than 30 throughout stance). Cerebellar Ataxic Gait Subject Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Diagnosis of either Friedreich's or spinocerebellar ataxia. Subject with Lower Limb Amputation Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Has been using the prosthetic limb for at least 6 months for independent ambulation prior to gait analysis at CGMA. ● Below knee or above knee amputation.
PI: Worster, Kate
  • 720-777-8216
  • worsterk@gmail.com
Would you like to participate in a study to improve the understanding of how emotions and symptom distress affect adherence to hormonal therapy in breast cancer? 13-0371
The purpose of this study is to understand how emotional factors and symptom distress affect adherence to hormonal therapy in women that have completed all other treatment for breast cancer.   
Women Breast Cancer Survivor Age 21-70 years old Within 24 months of starting hormonal therapy: Aromatase Inhibitors or Tamoxifen (Aromatase Inhibitors, Exemestane (aromasin), Letrolzole (Femara), Anastrozole (Arimidex).
PI: Grossman, Vicki
  • 720-352-3316
  • Vicki.Grossman@ucdenver.edu
Pharmacokinetics Research Study of Nontuberculous Mycobacteria Antibiotics in HEALTHY people and in people with CYSTIC FIBROSIS 14-1043
We are conducting a research study to test if levels of antibiotics used to treat nontuberculous mycobacteria infections are different between people with and without cystic fibrosis. The goal of our study is to provide recommendations for treatment of CF patients with lung disease due to nontuberculous mycobacterial infection.
Teenagers and adults who are either healthy or who have cystic fibrosis and are 16 to 45 years old may be eligible to participate in this study.
PI: Martiniano, Stacey
  • 720-777-2945
  • Meg.Anthony@childrenscolorado.org
Have the Flu? Living with a chronic medical condition, too? 11-0101
Influenza (the flu) can be life-threatening. Approximately 24,000 people in the United States die each year of this disease. We are conducting a study to determine whether treating patients with a combination of several drugs instead of just one helps them to get better faster.
You qualify for our study if you: •Have been diagnosed with the flu •Are at least 18 years of age •Have an existing medical condition that puts you at increased risk for complications from the flu—conditions such as diabetes; heart, lung, and kidney disease; COPD; and asthma
PI: Barron, Michelle
  • 303-724-0712
  • Graham.Ray@ucdenver.edu
Healthy Postmenopausal Women Needed for Cardiovascular Research Study 14-0532
The purpose of this study is to investigate how the health and function of arteries respond to estrogen, resveratrol, and exercise.
Postmenopausal women between the ages of 50-70 years, nonsmokers, not currently taking hormone replacement therapy or exercising vigorously more than 2 days per week.
PI: Moreau, Kerrie
  • 303-724-7465
  • cemal.ozemek@ucdenver.edu
Would your child like to participate in groundbreaking research and earn money? 12-1587
We are looking for healthy controls to participate in a research study investigating the cause of idiopathic scoliosis in adolescents.
Girls, 11-12 years old, do not have scoliosis or any other skeletal disorders, a BMI under 20 kg/m2, have not yet started their period, and have no family history of scoliosis
PI: Hadley Miller , Nancy
  • 720-777-4626
  • robin.baschal@childrenscolorado.org
Do you or someone you know have a food allergy to soy? 14-0097
We are studying the accuracy of a food allergy blood test.  
-Are age 1 to 21 and -Do have an IgE level greater than 0.35 to wheat OR soy or -Have had a positive skin test to wheat OR soy or -Have a clinically diagnosed wheat OR soy allergy -Do NOT use >500 micrograms/day fluticasone or equivalent -Do NOT have severe asthma, daily oral steroid dosing, or asthma requiring hospitalization within a year or an ER visit in the past 6 months -Do NOT have active EoE (or recently diagnosed) -Have NOT used biologic or allergen immunotherapy within the past year
PI: Fleischer, David
  • 720-777-2569
  • Hannah.Gilbert@childrenscolorado.org
Participants Needed For Research on Military Veterans And Service Dogs 14-2041
The purpose of this study is to explore the relationship between military veterans and their service dogs. Veterans will participate in one on one interviews.
Are you a military veteran? Do you have a service dog? Are you 18-89 years old? If you answered yes to the above, contact C-P.A.W.W. today.
PI: Krause-Parello, Cheryl
  • (303)-724-8282
  • CPAWW@ucdenver.edu
Pregnant Particpants Needed 13-3019
Pregnant women are invited to participate in a research study which plans to learn more about antibody (a substance produced by the body to fight disease) levels in mothers and infants whose mothers have received the Group B Strep vaccine between 23-34 6/7 weeks of their current pregnancy.  The study will also look at antibody levels in mother's breast milk.
You may be eligible to participate in this research study if: -You are a healthy pregnant woman 18-40 years of age -You are at 24 0/7- 34 6/7 weeks pregnant -You are planning to breastfeed for at least 90 days after delivery -You will delivery at the University of Colorado Hospital
PI: Gibbs, Ronald
  • 303-724-7807
  • jocelyn.phipers@ucdenver.edu
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • Brittany Kling
  • Brittany.Kling@ucdenver.edu
Apoyo con Cariño: Improving Palliative Care for Latinos with Cancer 12-0592
We want to understand if a patient navigator can help Latino patients and their family caregivers deal with cancer. Our project hopes to improve palliative or comfort care to patients with advanced cancer. The goal is to prevent or relieve suffering for people facing serious illness. Research is needed to find out if a patient navigator can help patients and family caregivers.
Adults (18 years and older) who self-identify as Latino and have Stage III-IV cancer.
PI: Fischer MD, Stacy
  • 303-724-7410
  • danielle.kline@ucdenver.edu
Seeking Adults with NO History of Eczema, Allergies or Asthma HS-2581
The purpose of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Males and females between 18 and 64years of age with no history of Allergies, Eczema, or Asthma
PI: Leung, Donald
  • 303-270-2222
  • lairsmithj@njhealth.org
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study HS-2678
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
PI: Bowler, Russell
  • 303-270-2827
  • HerrudT@njHealth.org
Psychiatric Medication Study 11-0965
We are looking for volunteers to participate in a research study investigating how psychiatric medications are processed in people who are diagnosed with HIV-1 compared to subjects who are on psychiatric medications who are HIV-negative. You can participate in this study if you are HIV negative and taking certain psychiatric medications.
To Qualify: Must between the ages of  2 to <25 years; Be HIV-Negative; On a steady dose of Psychiatric Medication (Celexa, Lexapro, Risperdal, Zoloft, Prozac, Paxil or generic equivalents)
PI: McFarland, Elizabeth
  • 720-777-6257
  • jenna.wallace@childrenscolorado.org
HEALTHY MEN AND WOMEN 60-85 YEARS OLD Wanted to participate in a research study 13-2594
To test whether interrupting prolonged sitting with short bouts of moderate intensity walking can improve health
We are looking for men and women who:  Are age 60-85 years old  Healthy – no diagnosed disease  Not on glucose lowering medication  Do not participate in regular exercise  Ambulatory – able to walk without assistance  Are non-smokers
PI: Lyden, Kate
  • Kate Lyden
  • kate.lyden@ucdenver.edu
Healthy Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
A Study to Determine the Effectiveness of Seeing Dermatologist Online Compared to In-Person 14-0585
The purpose of the study is to see whether seeing a dermatologist online is just as effective as seeing one in-person. Help us determine whether online-based model is cost-saving and more efficient compared to face-to-face visits!
In order to qualify for the study, you must be 18 years or older and have psoriasis. You must have access to the internet, and a digital camera or a mobile phone with a camera.
PI: Armstrong, April
  • 720-848-3607
  • aleksandra.florek@ucdenver.edu
Do You or Someone You Care for Suffer from Troublesome Drooling? 13-2237
A research study is being conducted to evaluate an investigational product for Sialorrhea (troublesome drooling).
You or your loved one may be eligible to participate if you meet the following criteria: 1. Have a diagnosis of Parkinson’s disease, adult cerebral palsy, ALS, stroke, traumatic brain injury, oral cancer, or side effects of medication, or any other condition that causes Sialorrhea or troublesome drooling 2. Have never received any type of treatment using Botulinum toxin type B 3. Have ability & availability to participate in a study for up to 1 year
PI: Klepitskaya, Olga
  • 303-724-8305
  • kalie.petefish@ucdenver.edu
Parkinson's Disease Research Study 14-0879
clinical research study to look at the safety and effectiveness of an investigational medication, ADS-5102 (amantadine HCl) extended release capsules, for troublesome dyskinesia in subjects with Parkinson’s disease.
You may be eligible if you have Parkinson's Disease, currently take levodopa, and are experiencing troublesome dyskinesia (involuntary twisting and turning).
PI: Leehey, Maureen
  • 303-724-8305
  • Kalie.Petefish@ucdenver.edu
Type 2 Diabetes Medication Research Study 13-2015
Studying the effects of sitagliptin (a diabetes medication) on exercise capacity in people with type 2 diabetes
-Be a man or woman between 22 and 70 years old -Be generally healthy, with type 2 diabetes -Be taking metformin only for your diabetes -Be a non-smoker -Have a Body Mass Index greater than 25.0
PI: Regensteiner, Judith
  • 303-724-2255
  • katie.rogers@ucdenver.edu
If you child suffers from rashes or skin allergies he or she may qualify to take part in a research study. 12-1208
To test seven new antigens on the child and adolescent population to add to the current standard test
Children and adolescents 6-17 diagnosed with contact dermatitis or may have contact dermatitis who are willing to wear test patches for 2 days and are available for follow-up visits
PI: Dunnick, Cory
  • 303-724-9155
  • Teresa.Derian@ucdenver.edu
Healthy Females needed! Ages 11 to 29 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money.  Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 29 who are right-handed, free of medication with no serious medical condition or permanent metal implants or braces/retainers.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
We are looking for Healthy Women to participate in a research study on.....Females, Aging, Metabolism, and Exercise (FAME) 12-1157
To examine the role that female sex hormones play in metabolism, energy expenditure, physical activity and chronic disease.
Healthy women 40-60 who have regular menstrual cycles and using no hormonal contraceptives
PI: Kohrt, Wendy
  • 720-848-6399
  • Kimberly.Harner@ucdenver.edu
Do you have Diabetes? 13-0131
To find the best combination drug treatment for type 2 diabetes
Persons who have had diabetes for less than 5 years and metformin is the only diabetes medication you are taking.
PI: Rasouli, Neda
  • 720-848-7174
  • Bradley.wine@ucdenver.edu
Type 1 Diabetes Research Study 11-0693
To study the effects of an FDA-approved medication on metabolism and blood vessel function.
Person 25-50 with type 1 diabetes who exercise vigorously less than four times per week and have normal blood pressure
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
CHILDHOOD and ADOLESCENT MIGRAINE PREVENTION STUDY 12-0776
to test two medicines for migraine prevention in children and teens. We want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency.
Children 8-17 who have migraine headaches
PI: Kedia, Sita
  • 720-777-8588
  • headacheresearch@childrenscolorado.org

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 557.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 557.
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy” – Sponsor SOTIO Sponsor Protocol No. SP005 WIRB Protocol No. 20141765
Flaig, Thomas13-2709
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer Sponsor Protocol No. INCB 18424-268 WIRB Protocol No. 20141874
Elias, Anthony14-0356
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A PHASE 1B, DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-06342674 (RN168) IN SUBJECTS WITH MULTIPLE SCLEROSIS (MS) Sponsor Protocol No. B4351002 WIRB Protocol No. 20141635
Vollmer, Timothy14-0555
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction with Midazolam, and Safety and Tolerability in Patients with Advanced Malignancies Sponsor Protocol No. OPZ009 WIRB Protocol No. 20141700
Gore, Lia14-0589
Evaluation of the Effectiveness of Evolution® Biliary Stent System – Fully Covered. Sponsor Protocol No. 10-014. WIRB Protocol No. 20142167
Shah, Raj14-0602
RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE−POSITIVE ADVANCED NON−SMALL CELL LUNG CANCER Sponsor Protocol No. BO28984 WIRB Protocol No. 20140921
Camidge, David14-0643
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects with Adult Solid Tumors. Sponsor Protocol No. LOXO-TRK-14001. WIRB Protocol No. 20142018
Doebele, Robert14-0886
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy. Sponsor Protocol No. ALDOXORUBICIN-PE-STS-01. WIRB Protocol No. 20141245
Elias, Anthony14-1004
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 Hours (7 Days) of Use Study Sponsor Protocol No. CEP292/Z25/B WIRB Protocol No. 20140632
Garg, Satish14-1040
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies Sponsor Protocol No. ORTE-01-14-US WIRB Protocol No. 20141629
Jimeno, Antonio14-1055
A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are &ge; 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy Sponsor Protocol No. M14-358 WIRB Protocol No. 20141655
Pollyea, Daniel14-1142
A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus. Sponsor Protocol No. KCP-330-006. WIRB Protocol No. 20141119
Jimeno, Antonio14-1152
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors Sponsor Protocol No. CLC-101 WIRB Protocol No. 20141911
Eckhardt, Sue14-1201
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the Eye Sponsor Protocol No. 32-007 WIRB Protocol No. 20111432
Palestine, Alan14-1279
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION. Sponsor Protocol No. GX29185. WIRB Protocol No. 20141609
Oliver, Scott14-1281
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB). Sponsor Protocol No. M14-227. WIRB Protocol No. 20141710
Everson, Greg14-1284
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RPC4046 IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS. Sponsor Protocol No. RPC02-201. WIRB Protocol No. 20140555
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC) Sponsor Protocol # C26002 WIRB Protocol # 20141183
Messersmith, Wells14-1305
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC). Sponsor Protocol No. C26003. WIRB Protocol No. 20141223
Messersmith, Wells14-1306


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more